Interphase fluorescence in situ hybridization (FISH) and TP53 mutation analyses are not essential to diagnose CLL but help predict the treatment response and should guide therapeutic decisions [12]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.